32 results on '"Vilella, Carles"'
Search Results
2. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension
- Author
-
Guillén-Del-Castillo, Alfredo, Meseguer, Manuel López, Fonollosa-Pla, Vicent, Giménez, Berta Sáez, Colunga-Argüelles, Dolores, Revilla-López, Eva, Rubio-Rivas, Manuel, Ropero, Maria Jose Cristo, Argibay, Ana, Barberá, Joan Albert, Salas, Xavier Pla, Meñaca, Amaya Martínez, Vuelta, Ana Belén Madroñero, Padrón, Antonio Lara, Comet, Luis Sáez, Morera, Juan Antonio Domingo, González-Echávarri, Cristina, Mombiela, Teresa, Ortego-Centeno, Norberto, González, Manuela Marín, Tolosa-Vilella, Carles, Blanco, Isabel, Subías, Pilar Escribano, and Simeón-Aznar, Carmen Pilar
- Published
- 2022
- Full Text
- View/download PDF
3. Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension
- Author
-
Guillén-Del-Castillo, Alfredo, Meseguer, Manuel López, Fonollosa-Pla, Vicent, Giménez, Berta Sáez, Colunga-Argüelles, Dolores, Revilla-López, Eva, Rubio-Rivas, Manuel, Ropero, Maria Jose Cristo, Argibay, Ana, Barberá, Joan Albert, Salas, Xavier Pla, Meñaca, Amaya Martínez, Vuelta, Ana Belén Madroñero, Padrón, Antonio Lara, Comet, Luis Sáez, Morera, Juan Antonio Domingo, González-Echávarri, Cristina, Mombiela, Teresa, Ortego-Centeno, Norberto, González, Manuela Marín, Tolosa-Vilella, Carles, Blanco, Isabel, Subías, Pilar Escribano, and Simeón-Aznar, Carmen Pilar
- Published
- 2022
- Full Text
- View/download PDF
4. Anti–Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature
- Author
-
Iniesta Arandia, Nerea, Espinosa, Gerard, Guillén del Castillo, Alfredo, Tolosa-Vilella, Carles, Colunga-Argüelles, Dolores, González de Echávarri Pérez de Heredia, Cristina, Lledó, Gema M., Comet, Luis Sáez, Ortego-Centeno, Norberto, Vargas Hito, José Antonio, Rubio-Rivas, Manuel, Freire, Mayka, Ríos-Blanco, Juan José, Rodríguez-Carballeira, Mónica, Trapiella-Martínez, Luis, Fonollosa-Pla, Vicent, and Simeón-Aznar, Carmen Pilar
- Published
- 2022
- Full Text
- View/download PDF
5. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study
- Author
-
Rubio-Rivas, Manuel, Corbella, Xavier, Pestaña-Fernández, Melany, Tolosa-Vilella, Carles, Guillen-del Castillo, Alfredo, Colunga-Argüelles, Dolores, Trapiella-Martínez, Luis, Iniesta-Arandia, Nerea, Castillo-Palma, María Jesús, Sáez-Comet, Luis, Egurbide-Arberas, María Victoria, Ortego-Centeno, Norberto, Freire, Mayka, Vargas-Hitos, Jose Antonio, Ríos-Blanco, Juan José, Todolí-Parra, Jose Antonio, Rodríguez-Carballeira, Mónica, Marín-Ballvé, Adela, Segovia-Alonso, Pablo, Pla-Salas, Xavier, Madroñero-Vuelta, Ana Belén, Ruiz-Muñoz, Manuel, Fonollosa-Pla, Vicent, Simeón-Aznar, Carmen Pilar, on behalf of RESCLE investigators, Autoimmune Diseases Study Group (GEAS), Callejas Moraga, E, Calvo, E., Carbonell, C., Castillo, M. J., Chamorro, A. J., Colunga, D., Corbella, X., Egurbide, M. V., Espinosa, G., Fonollosa, V., Freire, M., García Hernández, F. J., González León, R., Guillén del Castillo, A., Iniesta, N., Lorenzo, R., Madroñero, A. B., Marí, B., Marín, A., Ortego-Centeno, N., Pérez Conesa, M., Pestaña, M., Pla, X., Ríos Blanco, J. J., Rodríguez Carballeira, M., Rubio Rivas, M., Ruiz Muñoz, M., Sáez Comet, L., Segovia, P., Simeón, C. P., Soto, A., Tarí, E., Todolí, J. A., Tolosa, C., Trapiella, L., Vargas Hitos, J. A., and Verdejo, G.
- Published
- 2018
- Full Text
- View/download PDF
6. Prognostic implications of extra-hepatic clinical manifestations, autoimmunity and microscopic nail capillaroscopy in patients with primary biliary cirrhosis
- Author
-
Marí-Alfonso, Begoña, Amengual-Guedan, María José, Vergara-Gómez, Mercè, Simeón-Aznar, Carmen Pilar, Fonollosa-Plà, Vicente, Jove-Buxeda, Esther, Oliva-Morera, Juan, and Tolosa-Vilella, Carles
- Published
- 2016
- Full Text
- View/download PDF
7. Quantitative videocapillaroscopy correlates with functional respiratory parameters: a clue for vasculopathy as a pathogenic mechanism for lung injury in systemic sclerosis
- Author
-
Guillén-Del-Castillo, Alfredo, Simeón-Aznar, Carmen Pilar, Callejas-Moraga, Eduardo L., Tolosa-Vilella, Carles, Alonso-Vila, Serafín, Fonollosa-Pla, Vicente, and Selva-O’Callaghan, Albert
- Published
- 2018
- Full Text
- View/download PDF
8. Correction to: First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study
- Author
-
Rubio-Rivas, Manuel, Corbella, Xavier, Pestaña-Fernández, Melany, Tolosa-Vilella, Carles, Castillo, Alfredo Guillen-del, Colunga-Argüelles, Dolores, Trapiella-Martínez, Luis, Iniesta-Arandia, Nerea, Castillo-Palma, María Jesús, Sáez-Comet, Luis, Egurbide-Arberas, María Victoria, Ortego-Centeno, Norberto, Freire, Mayka, Vargas-Hitos, Jose Antonio, Ríos-Blanco, Juan José, Todolí-Parra, Jose Antonio, Rodríguez-Carballeira, Mónica, Marín-Ballvé, Adela, Segovia-Alonso, Pablo, Pla-Salas, Xavier, Madroñero-Vuelta, Ana Belén, Ruiz-Muñoz, Manuel, Fonollosa-Pla, Vicent, Simeón-Aznar, Carmen Pilar, on behalf of RESCLE investigators, and Autoimmune Diseases Study Group (GEAS)
- Published
- 2018
- Full Text
- View/download PDF
9. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
- Author
-
Simeón-Aznar, Carmen Pilar, Fonollosa-Plá, Vicent, Tolosa-Vilella, Carles, Selva-O’Callaghan, Albert, Solans-Laqué, Roser, and Vilardell-Tarrés, Miquel
- Published
- 2011
- Full Text
- View/download PDF
10. Olanzapine-induced agranulocytosis: A case report and review of the literature
- Author
-
Tolosa-Vilella, Carles, Ruiz-Ripoll, Ada, Mari-Alfonso, Begoña, and Naval-Sendra, Elsa
- Published
- 2002
- Full Text
- View/download PDF
11. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
- Author
-
Pestaña-Fernández, Melani, Rubio-Rivas, Manuel, Tolosa-Vilella, Carles, Guillén-Del-Castillo, Alfredo, Colunga-Argüelles, Dolores, Argibay, Ana, Marí-Alfonso, Begoña, Marín-Ballvé, Adela, Pla-Salas, Xavier, Chamorro, Antonio-J, Castro-Salomó, Antoni, Madroñero-Vuelta, Ana Belén, Sánchez-García, María Esther, Sáez-Comet, Luis, González-Echávarri, Cristina, Ortego-Centeno, Norberto, Vargas-Hitos, José Antonio, Todolí-Parra, José Antonio, Trapiella-Martínez, Luis, and Lledó, Gema María
- Subjects
KIDNEY disease diagnosis ,CELL receptors ,CONFIDENCE intervals ,REPORTING of diseases ,ENDOTHELINS ,FINGERS ,KIDNEY diseases ,LONGITUDINAL method ,MEDICAL records ,PULMONARY hypertension ,SYSTEMIC scleroderma ,TIME ,DISEASE incidence ,DISEASE prevalence ,RETROSPECTIVE studies ,PHOSPHODIESTERASE inhibitors ,DESCRIPTIVE statistics ,ACQUISITION of data methodology ,SKIN ulcers ,CHEMICAL inhibitors ,DISEASE complications - Abstract
Introduction Endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i) are beneficial in pulmonary arterial hypertension (PAH) and digital ulcers (DU) and prevent from DU recurrences. Our study aimed to determine the difference in the incidence rate of PAH and scleroderma renal crisis (SRC) in patients with SSc and DU (SSc-DU) under ERAs/PDE5i or without treatment. Methods We conducted a retrospective cohort study including SSc-DU patients from the Spanish Scleroderma Registry (RESCLE). The primary outcome was the incidence rate of PAH and SRC in patients under ERAs/PDE5i or not. Results Some 544 patients out of 1817 (29.9%) in the RESCLE database had DU, 221 (40.6%) under ERAs/PDE5i and 323 (59.4%) not. The incidence rate (95% CI) difference between patients under treatment or not under did not reach statistical significance in PAH [−0.1 (−4.8, 4.69), P = 0.988] or in SRC [0.7 (−2.2, 3.7), P = 0.620]. However, the time from the first DU to the diagnosis of SRC was delayed in treated patients [mean (s. d.) 7.6 (5.8) years vs 2.9 (5.3); P = 0.021]. The dcSSc subset was more prevalent in the treatment group (36 vs 26%; P = 0.018), along with anti-topoisomerase I antibodies (34 vs 18%; P < 0.001) and tendon friction rubs (12 vs 6%; P = 0.038), whereas the lcSSc subset was more prevalent in the no-treatment group (57 vs 66%; P = 0.031) along with ACA (37 vs 46%; P = 0.031). Conclusion There was no difference in the incidence rate of PAH and SRC between groups. However, treatment with ERAs and/or PDE5i appeared to delay the occurrence of SRC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study.
- Author
-
Pestaña-Fernández, Melani, Rubio-Rivas, Manuel, Tolosa-Vilella, Carles, Guillén-Del-Castillo, Alfredo, Freire, Mayka, Vargas-Hitos, Jose Antonio, Todolí-Parra, Jose Antonio, Rodríguez-Carballeira, Mónica, Marín-Ballvé, Adela, Espinosa, Gerard, Colunga-Argüelles, Dolores, Ortego-Centeno, Norberto, Trapiella-Martínez, Luis, Carbonell-Muñoz, Cristina, Pla-Salas, Xavier, Perales-Fraile, Isabel, Corbella, Xavier, Fonollosa-Pla, Vicent, Simeón-Azna, Carmen Pilar, and Simeón-Aznar, Carmen Pilar
- Published
- 2020
- Full Text
- View/download PDF
13. Registry of the Spanish Network for Systemic Sclerosis
- Author
-
Simeón-Aznar, C.P., Fonollosa-Plá, V., Tolosa-Vilella, Carles, Espinosa-Garriga, G., Campillo-Grau, M., Ramos-Casals, M., García-Hernández, F.J., Castillo-Palma, M.J., Sánchez-Román, J., Callejas-Rubio, J.L., Ortego-Centeno, N., Egurbide-Arberas, M.V., Trapiellla-Martínez, L., Caminal-Montero, L., Sáez-Comet, L., Velilla-Marco, J., Camps-García, M.T., de Ramón-Garrido, E., Esteban-Marcos, E.M., Pallarés-Ferreres, L., Navarrete-Navarrete, N., Vargas-Hitos, J.A., de la Torre, R. Gómez, Salvador-Cervello, G., Rios-Blanco, J.J., and Vilardell-Tarrés, M.
- Subjects
Adult ,Male ,Scleroderma, Systemic ,Observational Study ,Middle Aged ,Risk Factors ,Spain ,Cause of Death ,Humans ,Female ,Registries ,Research Article ,Aged ,Retrospective Studies - Abstract
Systemic sclerosis (SSc) is a rare, multisystem disease showing a large individual variability in disease progression and prognosis. In the present study, we assess survival, causes of death, and risk factors of mortality in a large series of Spanish SSc patients. Consecutive SSc patients fulfilling criteria of the classification by LeRoy were recruited in the survey. Kaplan–Meier and Cox proportional-hazards models were used to analyze survival and to identify predictors of mortality. Among 879 consecutive patients, 138 (15.7%) deaths were registered. Seventy-six out of 138 (55%) deceased patients were due to causes attributed to SSc, and pulmonary hypertension (PH) was the leading cause in 23 (16.6%) patients. Survival rates were 96%, 93%, 83%, and 73% at 5, 10, 20, and 30 years after the first symptom, respectively. Survival rates for diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc were 91%, 86%, 64%, and 39%; and 97%, 95%, 85%, and 81% at 5, 10, 20, and 30 years, respectively (log-rank: 67.63, P
- Published
- 2015
14. Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry.
- Author
-
García-Hernández, Francisco J., Castillo-Palma, María J., Tolosa-Vilella, Carles, Guillén-del Castillo, Alfredo, Rubio-Rivas, Manuel, Freire, Mayka, Vargas-Hitos, José A., Todolí-Parra, José A., Rodríguez-Carballeira, Mónica, Espinosa-Garriga, Gerard, Colunga-Argüelles, Dolores, Ortego-Centeno, Norberto, Trapiella-Martínez, Luis, Rodero-Roldán, María M., Pla-Salas, Xavier, Perales-Fraile, Isabel, Pons-Martín del Campo, Isaac, Chamorro, Antonio J., Fernández-de la Puebla Giménez, Rafael A., and Madroñero-Vuelta, Ana B.
- Subjects
SYSTEMIC scleroderma ,PULMONARY hypertension ,INTERSTITIAL lung diseases ,PULMONARY artery ,HEART diseases - Abstract
Introduction: Our objective was to evaluate the pulmonary hypertension (PH) data for Spanish patients with systemic sclerosis (SSc), define the PH types and determine the associated factors.Method: Descriptive study of PH-related data from the multicentre RESCLE registry. Estimated systolic pulmonary artery pressure (esPAP), measured via echocardiogram was considered elevated if ≥ 35 mmHg. Left heart disease (LHD) and interstitial lung disease (ILD) were identified. When performed, data from right heart catheterisation (RHC) were collected.Results: esPAP was elevated in 350 of 808 patients (43.3%). One hundred and forty-four patients (17.8%) were considered to have PH (88 via RHC and the rest due to elevated esPAP along with evidence of significant LHD or ILD): PAH 3.7%, secondary to ILD 8.3%, secondary to LHD 2.8% and unclassified 3%. Prevalence of elevated esPAP was greater in diffuse SSc (dSSc) than in limited scleroderma (lSSc) (50.5 vs. 42.2%, p 0.046). In the group with elevated esPAP, a lower prevalence of anti-centromere antibodies (41.9% vs. 52.3%, p 0.006) and a greater prevalence of anti-topoisomerase-1 antibodies (ATA) (25.1% vs. 18.6%, p 0.04) were observed compared to the group with normal esPAP. Patients with elevated esPAP had a lower rate of digital ulcers (50.6% vs. 60.2%, p 0.007) and esophageal involvement (83.6% vs. 88.7%, p 0.07) and higher rate of renal crisis (4.6% vs. 1.8%, p 0.066).Conclusions: Prevalence of PAH was lower than expected (3.7%). Probability of having elevated esPAP was higher among patients with dSSc and among those with ATA. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Intravenous Cyclophosphamide Pulse Therapy in the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease : A Long Term Study
- Author
-
Simeón-Aznar, Carmen Pilar, Fonollosa Pla, Vicent, Tolosa-Vilella, Carles, Selva-O'Callaghan, A., Solans-Laqué, Roser, Palliza, E., Muñoz Gall, Xavier, Vilardell-Tarrés, M., and Universitat Autònoma de Barcelona. Departament de Medicina
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Vital capacity ,Cyclophosphamide ,Interstitial lung disease ,cyclophosphamide ,Article ,FEV1/FVC ratio ,DLCO ,Interquartile range ,Internal medicine ,medicine ,Lung volumes ,interstitial lung disease ,business.industry ,respiratory system ,medicine.disease ,Surgery ,respiratory tract diseases ,Regimen ,Cardiology ,Systemic sclerosis ,business ,medicine.drug - Abstract
Objective: Interstitial lung disease (ILD) frequently complicates systemic sclerosis (SSc). Cyclophosphamide (CYC) is a promising immunosuppressive therapy for SSc-related ILD. Our objective was to investigate the effectiveness of an intravenous CYC (iv CYC) pulse regime in SSc-related ILD during treatment and thereafter. Methods: In a prospective observational study ten consecutive patients with SSc-related ILD were treated with iv CYC in a pulse regime lasting from 6 to 24 months. Clinical status, pulmonary functional testing (PFT) and high resolution com- puted tomography (HRCT) of the chest were evaluated at enrolment and 6, 12 and 24 months thereafter. After treatment withdrawal, patients were followed up every 6 months with PFT and chest HRCT to monitor lung disease. Results: Clinical improvement was apparent in 8 out of 10 patients. The median values of forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) as well as ground-glass pattern on HRCT did not change significantly after 6, 12 and 24 months of therapy. The follow-up continued in 8 out of 10 patients after treatment withdrawal for a median of 26.5 months (range: 12-48 months). The final median FVC was 54.5% of predicted value (interquartile range, IQR= 31.6%-94%). Only one patient suffered a FVC deterioration greater than 10%, even though less than 160 ml. The final median DLCO was 68% of predicted value (IQR=38.3-83.6%). Only 2 patients who developed pulmonary arterial hypertension deteriorated their DLCO values of more than 15%. Conclusions: An iv CYC pulse regimen over 24 months may stabilize pulmonary activity in patients with SSc-related ILD during the course of treatment and for a median of 26.5 months thereafter.
- Published
- 2008
16. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry.
- Author
-
Tolosa-Vilella, Carles, Morera-Morales, Maria Lluisa, Simeón-Aznar, Carmen Pilar, Marí-Alfonso, Begoña, Colunga-Arguelles, Dolores, Callejas_Rubio, José Luis, Rubio-Rivas, Manuel, Freire-Dapena, Maika, Guillén-del Castillo, Alfredo, Iniesta-Arandia, Nerea, Castillo-Palma, Maria Jesús, Egurbide-Arberas, Marivi, Trapiellla-Martínez, Luis, Vargas-Hitos, José A, Todolí-Parra, José Antonio, Rodriguez-Carballeira, Mónica, Marin-Ballvé, Adela, Pla-Salas, Xavier, Rios-Blanco, Juan José, and Fonollosa-Pla, Vicent
- Abstract
Objective Digital ulcers (DU) are the most common vascular complication of systemic sclerosis (SSc). We compared the characteristics between patients with prior or current DU with those never affected and evaluated whether a history of DU may be a predictor of vascular, organ involvement, and/or death in patients with SSc. Methods Data from SSc patients with or without prior or current DU were collected by 19 referral centers in an ongoing registry of Spanish SSc patients, named Registro de ESCLErodermia (RESCLE). Demographics, organ involvement, autoimmunity features, nailfold capillary pattern, survival time, and causes of death were analyzed to identify DU related characteristics and survival of the entire series and according to the following cutaneous subsets—diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc), and SSc sine scleroderma (ssSSc). Results Out of 1326, 552 patients enrolled in the RESCLE registry had prior or current DU, 88% were women, the mean age was 50 ± 16 years, and the mean disease duration from first SSc symptom was 7.6 ± 9.6 years. Many significant differences were observed in the univariate analysis between patients with and without prior/current DU. Multivariate analysis identified that history of prior/current DU in patients with SSc was independently associated to younger age at SSc diagnosis, diffuse cutaneous SSc, peripheral vascular manifestations such Raynaud’s phenomenon, telangiectasia, and acro-osteolysis but no other vascular features such as pulmonary arterial hypertension or scleroderma renal crisis. DU was also associated to calcinosis cutis, interstitial lung disease, as well as worse survival. Multivariate analysis performed in the cutaneous subsets showed that prior/current DU were independently associated: (1) in dcSSc, to younger age at SSc diagnosis, presence of telangiectasia and calcinosis and rarely a non-SSc pattern on nailfold capillaroscopy; (2) in lcSSc, to younger age at SSc diagnosis, presence of Raynaud’s phenomenon as well as calcinosis cutis, interstitial lung disease, and higher incidence of death from all causes; and (3) in ssSSc, to younger age at first SSc symptom and greater incidence of death from all causes. Conclusions Digital ulcers develop in patients with SSc younger at diagnosis, mainly in patients with dcSSc and lcSSc, and they are associated to other peripheral vascular manifestations such as Raynaud’s phenomenon, telangiectasia, and acro-osteolysis but also to calcinosis, and interstitial lung disease. History of DU in SSc leads to worse survival, also noticeable for lcSSc and ssSSc subsets but not for dcSSc patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort.
- Author
-
Sáez-Comet, Luis, Pilar Simeón-Aznar, Carmen, Pérez-Conesa, Mercedes, Vallejo-Rodríguez, Carmen, Tolosa-Vilella, Carles, Iniesta-Arandia, Nerea, Colunga-Argüelles, Dolores, Victoria Egurbide-Arberas, Maria, Ortego-Centeno, Norberto, Antonio Vargas-Hitos, José, Freire-Dapena, Mayka, Rubio-Rivas, Manuel, José Ríos-Blanco, Juan, Trapiella-Martínez, Luis, Fonollosa-Pla, Vicent, Simeón-Aznar, Carmen Pilar, Egurbide-Arberas, Maria Victoria, Vargas-Hitos, José Antonio, Ríos-Blanco, Juan José, and RESCLE Investigators
- Published
- 2015
- Full Text
- View/download PDF
18. Registry of the Spanish Network for Systemic Sclerosis: Clinical Pattern According to Cutaneous Subsets and Immunological Status.
- Author
-
Simeón-Aznar, Carmen Pilar, Fonollosa-Plá, Vicent, Tolosa-Vilella, Carles, Espinosa-Garriga, Gerard, Ramos-Casals, Manel, Campillo-Grau, Mercedes, García-Hernández, Francisco José, Castillo-Palma, María Jesús, Sánchez-Román, Julio, Callejas-Rubio, José Luis, Ortego-Centeno, Norberto, Egurbide-Arberas, Maria Victoria, Trapiellla-Martínez, Luis, Gallego-Villalobos, María, Sáez-Comet, Luis, Velilla-Marco, José, Camps-García, María Teresa, de Ramón-Garrido, Enrique, Esteban Marcos, Eva María, and Pallarés-Ferreres, Lucio
- Abstract
Objective: To investigate the incidence of clinical and immunological characteristics of a large cohort of Spanish patients with scleroderma (SSc) and identifying factors associated with particular organ manifestations assessed by a nationwide cross-sectional analysis. Methods: We classified SSc patients in 4 subsets using a modification of LeRoy and Medsger classification that included: “prescleroderma” (pre-SSc), limited cutaneous SSc (lcSSc), diffuse cutaneous SSc (dcSSc), and SSc sine scleroderma (ssSSc). Fourteen Spanish centers participated in patient recruitment. On January 2008, the database included 916 consecutive Spanish SSc patients, 801 women (87.4%) and 115 men (12.6%), all of whom fulfilled the classification criteria proposed by LeRoy and Medsger. Epidemiological, clinical, and laboratory data were collected according to a standard protocol. Mean age at diagnosis was 51.2 ± 15.1 years and mean age at disease onset was 44.9.0 ± 15.8 years. lcSSc was the most frequent subset (61.8%) followed by dcSSc (26.5%), ssSSc (7.5%), and preSSc (4%) subsets. Gender ratios were as follows: dcSSc subset, 200 women and 43 men (4.7:1); lcSSc subset, 503 women and 63 men (ratio 7.9:1), and ssSSc subset, 62 women and 7 men (ratio 8.9:1). Digital ulcers, interstitial lung disease (ILD), musculoeskeletal and esophageal involvement, and scleroderma renal crisis were more frequent in dcSSc than lcSSc and ssSSc subsets. The incidence of pulmonary arterial hypertension assessed by echocardiography was similar in all subsets but mean estimated systolic pulmonary arterial pressure was higher in ssSSc than in lcSSc subset (47.3 ± 23.9 mm Hg vs 39.6 ± 19.2 mm Hg; P < 0.03). Cardiac involvement was identified more frequently in ssSSc than in dcSSc and lcSSc subsets (49.3% vs 32.5% and 31.1%, respectively; P = 0.015 and P = 0.004 for both comparisons). Acro-osteolysis (8.2% vs 2.4%, P = 0.049), calcinosis (19.8% vs 7.2%, P < 0.05), and sicca syndrome (37.5% vs 14.5%, P < 0.0001) were more frequent in lcSSc than in ssSSc subsets. The frequency of clinical manifestations related to the presence of anticentromere antibodies or antitopoisomerase I antibodies was very similar to that identified in patients categorized to lcSSc and dcSSc, respectively. However, in multivariate studies, the ranking of the variables according to their overall explanatory effect on the model showed that the contributory effect of the antibody status was not greater than that of the clinical categorization into lcSSc and dcSSc for the majority of disease manifestations, but, in important manifestations, as ILD, absence of anticentromere antibodies was an independent predictor factor. Conclusions: The classification of SSc into dcSSc, lcSSc, and ssSSc subsets is the one that most closely reflects the natural history of the disease, as they presented clear clinical differences. The immunological profile helps to define important visceral alteration as ILD. Finally, to improve early diagnosis of SSc, patients with preSSc should be considered both to trace the true evolution of the disease and to define which patients could benefit from therapeutic measures able to prevent the appearance of visceral involvements. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
19. Remote Sensing and Skywave Digital Communication from Antarctica.
- Author
-
Bergadà, Pau, Deumal, Marc, Vilella, Carles, Regué, Joan R., Altadill, David, and Marsal, Santi
- Subjects
REMOTE sensing ,DIGITAL communications ,IONOSPHERE ,ORTHOGONAL frequency division multiplexing ,TECHNOLOGICAL innovations ,RADAR transmitters ,OBLIQUE coordinates - Abstract
This paper presents an overview of the research activities undertaken by La Salle and the Ebro Observatory in the field of remote sensing. On 2003 we started a research project with two main objectives: implement a long-haul oblique ionospheric sounder and transmit the data from remote sensors located at the Spanish Antarctic station Juan Carlos I to Spain. The paper focuses on a study of feasibility of two possible physical layer candidates for the skywave link between both points. A DS-SS based solution and an OFDM based solution are considered to achieve a reliable low-power low-rate communication system between Antarctica and Spain. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
20. Mesangioproliferative Glomerulonephritis and Antibodies to Phospholipids in a Patient with Acute Q Fever: Case Report.
- Author
-
Tolosa-Vilella, Carles, Rodríguez-Jornet, Angel, Font-Rocabanyera, Juli, and Andreu-Navarro, Xavier
- Abstract
Glomerulonephritis is a rare complication of Q fever and is usually associated with the chronic form of disease, i.e., infectious endocarditis. We describe a 31-year-old man with a self-limited acute febrile illness due to Coxiella burnetii infection who had acute renal failure secondary to mesangioproliferative glomerulonephritis. Antibodies to phospholipids were detected and suggested the diagnosis of Q fever in this case. [ABSTRACT FROM PUBLISHER]
- Published
- 1995
21. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort.
- Author
-
Trapiella-Martínez, Luis, Díaz-López, José Bernardino, Caminal-Montero, Luis, Tolosa-Vilella, Carles, Guillén-Del Castillo, Alfredo, Colunga-Argüelles, Dolores, Rubio-Rivas, Manuel, Iniesta-Arandia, Nerea, Castillo-Palma, María Jesús, Sáez-Comet, Luis, Egurbide-Arberas, María Victoria, Ortego-Centeno, Norberto, Freire, Mayka, Vargas-Hitos, Jose Antonio, Ríos-Blanco, Juan José, Todolí-Parra, Jose Antonio, Rodríguez-Carballeira, Mónica, Marín-Ballvé, Adela, Chamorro-Fernández, Antonio Javier, and Pla-Salas, Xavier
- Subjects
- *
SYSTEMIC scleroderma , *DISEASE progression , *ANTINUCLEAR factors , *DISEASE risk factors , *DIAGNOSIS , *THERAPEUTICS - Abstract
Objectives According to the existence of subclinical organ involvement pre-scleroderma should be divided into two subsets: very early and early disease. Pre-scleroderma patients included in the Spanish Scleroderma Registry (RESCLE) Cohort were reclassified into subsets. Differences were evaluated and the risk of progression to definite systemic sclerosis was estimated. Methods The characteristics of very early and early SSc patients were compared. A logistic regression model was used to determine the risk factors of progression. Results 1632 patients were included, 36 (2.2%) in the very early subset and 111 (6.8%) in the early subset. There were no differences in sex, age at disease onset, duration of Raynaud's phenomenon, antinuclear antibodies or capillaroscopic findings. Three (8.3%) very early SSc patients evolved to definite SSc, 2 (5.6%) of them meeting the ACR/EULAR 2013 criteria, unlike 31 (28%) early SSc patients, 20 (24%) of them meeting the criteria ( p = 0.034). Digestive involvement was an independent risk factor of progression (OR 17; 95% CI, 6.1–47.2). Conclusions The classification of early forms of scleroderma identifies patients with different prognostic risk of progression. The evolution to definite SSc is more frequent in early than in very early SSc patients. Digestive involvement is a risk factor of progression. An active assessment of organ damage in preclinical stages allows a correct classification and risk stratification, with implications for monitoring and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Corrigendum to 'Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation' [AUTREV 19-5 (2020) 102507].
- Author
-
Rubio-Rivas, Manuel, Corbella, Xavier, Guillén-del-Castillo, Alfredo, Tolosa Vilella, Carles, Colunga Argüelles, Dolores, Argibay, Ana, Vargas Hitos, José Antonio, Todolí Parra, José Antonio, González-Echávarri, Cristina, Ortego-Centeno, Norberto, Trapiella Martínez, Luis, Rodríguez Carballeira, Mónica, Marín Ballvé, Adela, Pla Salas, Xavier, Perales Fraile, Isabel, Chamorro, Antonio-J, Madroñero Vuelta, Ana Belén, Freire, Mayka, Ruiz Muñoz, Manuel, and González García, Andrés
- Subjects
- *
DIAGNOSIS , *MORTALITY , *FORECASTING , *TIME , *PATIENTS , *SCLERODERMA (Disease) - Published
- 2021
- Full Text
- View/download PDF
23. Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation.
- Author
-
Rubio-Rivas, Manuel, Corbella, Xavier, Guillén-del-Castillo, Alfredo, Tolosa Vilella, Carles, Colunga Argüelles, Dolores, Argibay, Ana, Vargas Hitos, José Antonio, Todolí Parra, José Antonio, González-Echávarri, Cristina, Ortego-Centeno, Norberto, Trapiella Martínez, Luis, Rodríguez Carballeira, Mónica, Marín Ballvé, Adela, Pla Salas, Xavier, Perales Fraile, Isabel, Chamorro, Antonio-J, Madroñero Vuelta, Ana Belén, Freire, Mayka, Ruiz Muñoz, Manuel, and González García, Andrés
- Subjects
- *
MULTIVARIATE analysis , *VISCERAL pain , *SYSTEMIC scleroderma , *SCLERODERMA (Disease) , *MORTALITY - Abstract
A few scores predicting the short-term risk of mortality in Systemic sclerosis (SSc) have been reported to date. Our study aimed to create a predictive 15-year all-cause mortality score at the time of the diagnosis of SSc. The study was based on the Spanish Scleroderma Registry (RESCLE). The cohort was split up in derivation (DC) and validation cohort (VC). A multivariate analysis to detect variables related to all-cause mortality within the first 15 years from SSc diagnosis was performed, assigning points to the rounded beta values to create the score (RESCLESCORE). 1935 SSc patients were included. The variables in the final model were as follows: age at diagnosis (+2 points > 65 years-old), male gender (+1 point), lcSSc subset (−1 point), mode of onset other than Raynaud's (+1 point), cancer (+1 point) and visceral involvement, such as ILD (+1 point), PAH (+1 point), heart (+1 point) and renal involvement (+2 points). Autoantibodies did not achieve statistical significance in the multivariate analysis. The 3 categories of risk to predict 15-year all-cause mortality at the time of diagnosis were as follows: low risk (5% vs. 7%, p =.189), intermediate risk (26.5% vs. 25.5%, p =.911) and high risk (47.8% vs. 59%, p =.316). The AUC was 0.799 (DC) vs. 0.778 (VC) (p =.530). In conclusion, the RESCLESCORE demonstrated an excellent ability to categorize SSc patients at the time of diagnosis in separate 15-year all-cause mortality risk strata at the time of diagnosis. • New score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis. • 3-risk strata categories. • AUC 0 0.799. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Nailfold videocapillaroscopy patterns in systemic sclerosis: implications for cutaneous subsets, disease features and prognostic value for survival.
- Author
-
Tolosa-Vilella C, Del Mar Rodero-Roldán M, Guillen-Del-Castillo A, Marín-Ballvé A, Boldova-Aguar R, Marí-Alfonso B, Feijoo-Massó C, Colunga-Argüelles D, Rubio-Rivas M, Trapiella-Martínez L, Iniesta-Arandia N, Callejas-Moraga E, García-Hernández FJ, Sáez-Comet L, González-Echávarri C, Ortego-Centeno N, Freire M, Vargas-Hitos JA, Ríos-Blanco JJ, Todolí-Parra JA, Rodríguez-Pintó I, Chamorro AJ, Pla-Salas X, Madroñero-Vuelta AB, Ruiz-Muñoz M, Fonollosa-Pla V, and Simeón-Aznar CP
- Subjects
- Humans, Female, Male, Prognosis, Microscopic Angioscopy, Scleroderma, Systemic complications, Scleroderma, Systemic diagnosis, Lung Diseases, Interstitial diagnosis
- Abstract
Objectives: To assess the associations and prognostic value of scleroderma patterns by nailfold videocapillaroscopy (NVC) in patients with systemic sclerosis (SSc) and cutaneous subsets., Methods: At baseline, 1356 SSc patients from the RESCLE registry were compared according to the scleroderma pattern as Late pattern and non-Late pattern, which included Early and Active patterns. Patient characteristics, disease features, survival time and causes of death were analysed., Results: Late pattern was identified in 540 (39.8%), and non-Late pattern in 816 (60.2%) patients (88% women; 987 lcSSc/251 dcSSc). Late pattern was associated to dcSSc (OR=1.96; p<0.001), interstitial lung disease (ILD) (OR=1.29; p=0.031), and scleroderma renal crisis (OR=3.46; p<0.001). Once the cutaneous subset was disregarded in an alternative analysis, both digital ulcers (DU) (OR=1.29; p<0.037) and anti-topoisomerase I antibodies (OR=1.39; p< 0.036) emerged associated with the Late pattern. By cutaneous subsets, associations with Late pattern were: (1) in dcSSc, acro-osteolysis (OR=2.13; p=0.022), and systolic pulmonary artery pressure >40 mmHg by Doppler echocardiogram (OR=2.24; p<0.001); and (2) in lcSSc, ILD (OR=1.38; p=0.028). Survival was reduced in dcSSc with Late pattern compared to non-Late pattern (p=0.049). Risk factors for SSc mortality in multivariate regression Cox analysis were age at diagnosis (HR=1.03; p<0.001), dcSSc (HR=2.48; p<0.001), DU (HR=1.38; p=0.046), ILD (HR=2.81; p<0.001), and pulmonary arterial hypertension (HR=1.99; p<0.001)., Conclusions: SSc patients with Late pattern more frequently present dcSSc and develop more fibrotic and vascular manifestations. Advanced microangiopathy by NVC identifies dcSSc patients at risk of reduced survival due to SSc-related causes.
- Published
- 2023
- Full Text
- View/download PDF
25. Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry.
- Author
-
González García A, Fabregate M, Manzano L, Guillén Del Castillo A, Rubio Rivas M, Argibay A, Marín Ballvé A, Rodríguez Pintó I, Pla Salas X, Marí-Alfonso B, Callejas Moraga E, Colunga Argüelles D, Sáez Comet L, González-Echávarri C, Ortego-Centeno N, Vargas Hitos JA, Todolí Parra JA, Trapiella Martínez L, Herranz Marín MT, Freire M, Chamorro AJ, Perales Fraile I, Madroñero Vuelta AB, Sánchez Trigo S, Tolosa Vilella C, Fonollosa Pla V, and Simeón Aznar CP
- Subjects
- Cohort Studies, Humans, Registries, Scleroderma, Diffuse, Scleroderma, Systemic, Telangiectasis, Ventricular Dysfunction, Left complications, Ventricular Dysfunction, Left diagnosis
- Abstract
Objectives: Left ventricular diastolic dysfunction (LVDD) remains poorly studied in Systemic Sclerosis (SSc). To determine the prevalence and to define factors associated with LVDD and survival in a large cohort of patients with SSc., Methods: An observational study was conducted with data from the multicentre Spanish Scleroderma Registry (RESCLE) to identify factors associated with LVDD and estimate survival., Results: Out of 1517 patients, 319 (21.0%) had LVDD. The subset of sine scleroderma SSc was associated to LVDD (14.7% vs. 10.6%, p =0.048), whilst diffuse cutaneous SSc was more prevalent in non-LVDD (16.0 % vs. 21.2%, p =0.041). Multivariable analysis identified that LVDD was associated with older age at diagnosis of SSc (OR 1.05; 95% CI 1.04 to 1.06), longer time from diagnosis (OR 1.04; 95% CI 1.03 to 1.06), presence of telangiectasia (OR 1.42; 95% CI 1.08 to 1.88), treatment with calcium channel blockers (CCB) (OR 1.51; 95% CI 1.16 to 1.96), and inversely related to angiotensin-converting-enzyme inhibitors (ACEi) use (OR 0.59; 95% CI 0.44 to 0.80). SSc patients with LVDD had increased mortality (23.8 vs. 17.4%, p =0.010) and shortened survival from the first SSc symptom (p =0.040), even though it was not found to be an independent risk factor for death., Conclusions: LVDD is relatively common in SSc patients, and it is associated with worst prognosis, older age, longer time from diagnosis of SSc, presence of telangiectasia and vasodilator treatment., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
26. Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature.
- Author
-
Iniesta Arandia N, Espinosa G, Guillén Del Castillo A, Tolosa-Vilella C, Colunga-Argüelles D, González de Echávarri Pérez de Heredia C, Lledó GM, Comet LS, Ortego-Centeno N, Vargas Hito JA, Rubio-Rivas M, Freire M, Ríos-Blanco JJ, Rodríguez-Carballeira M, Trapiella-Martínez L, Fonollosa-Pla V, and Simeón-Aznar CP
- Subjects
- Antibodies, Autoantibodies, Cohort Studies, Humans, Arthritis, Polymyositis diagnosis, Polymyositis epidemiology, Scleroderma, Systemic diagnosis, Scleroderma, Systemic epidemiology
- Abstract
Objectives: To assess the clinical profile of patients with anti-polymyositis/Scl (PM/Scl) antibodies in a cohort of Spanish patients with systemic sclerosis., Methods: From the Spanish Scleroderma Study Group database, we selected patients in whom PM/Scl antibodies had been tested. We compared demographic, clinical, laboratory, and survival data between patients with and without PM/Scl antibodies., Results: Seventy-two of 947 patients (7.6%) tested positive for PM/Scl antibodies. Patients with PM/Scl antibodies presented initially with more puffy fingers and arthralgias but less Raynaud phenomenon. Regarding cumulative manifestations, myositis and arthritis were more prevalent in patients with PM/Scl antibodies, as well as pulmonary fibrosis. On the contrary, patients with PM/Scl antibodies had less pulmonary hypertension. No difference in terms of survival at 5 and 10 years was noticed between the 2 groups., Conclusions: In systemic sclerosis patients from Spain, PM/Scl antibodies are associated with a distinct clinical profile. However, PM/Scl antibodies did not influence survival., Competing Interests: The authors declare no conflict of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
27. Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement.
- Author
-
Iniesta Arandia N, Espinosa G, Tolosa Vilella C, Guillén Del Castillo A, Rubio Rivas M, Freire M, Vargas Hitos JA, Todolí Parra JA, Rodríguez Carballeira M, Marín Ballvé A, Colunga Argüelles D, González de Echávarri Pérez de Heredia C, Ortego-Centeno N, Trapiella Martínez L, Pla Salas X, Chamorro AJ, Perales Fraile I, Ruiz Muñoz M, Fernández de la Puebla Giménez RÁ, Madroñero Vuelta AB, Pons Martín Del Campo I, Jiménez Pérez de Heredia I, González García A, Fonollosa Pla V, and Simeón Aznar CP
- Subjects
- Autoantibodies, Humans, Hypertension, Pulmonary, Lung Diseases, Interstitial, Scleroderma, Diffuse, Scleroderma, Systemic
- Abstract
Objectives: Diffuse cutaneous systemic sclerosis (dcSSc) is associated with anti-topoisomerase (ATA) whereas limited cutaneous (lcSSc) and sine scleroderma (ssSSc) are mainly associated with anti-centromere antibody (ACA). Serodiscordant patients were defined as lcSSc subjects with ATA, dcSSc with ACA, and ssSSc with ATA. The aim of the present study was to compare the clinical manifestations and prognosis between serodiscordant patients and their counterparts (those with lcSSc with ACA, dcSSc with ATA and ssSSc with ACA, respectively)., Methods: From the Spanish Scleroderma Registry we selected those patients for whom skin involvement (dcSSc, lcSSc or ssSSc) was detailed at baseline and last visit and ACA and ATA had been determined. Demographic, clinical characteristics, and survival data were compared according to the antibody status., Results: The whole cohort comprised 901 patients and six mutually exclusive groups were defined: lcSScACA in 511 (57%) patients, lcSScATA group in 87 (10%), dcSScATA group in 172 (19%), dcSScACA group in 21 (2%), ssSScACA group in 92 (10%), and ssSScATA group in 18 (2%) patients, respectively. Interstitial lung disease (ILD) and severe ILD were more frequent in patients with dcSScATA than in those with dcSScACA. Conversely, the prevalence of isolated pulmonary hypertension (without ILD) was higher in those with dcSScACA (15% vs. 2%; p=0.018). No differences were found regarding survival when comparing serodiscordant patients with the seroconcordants patients., Conclusions: In our cohort, the prevalence of serodiscordant SSc patients was low. They differed from their counterparts in some clinical manifestations. The management of patients with SSc should be guided by both serology and cutaneous subtype.
- Published
- 2020
28. Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain.
- Author
-
Callejas-Moraga EL, Guillén-Del-Castillo A, Marín-Sánchez AM, Roca-Herrera M, Balada E, Tolosa-Vilella C, Fonollosa-Pla V, and Simeón-Aznar CP
- Subjects
- Adult, Autoantibodies blood, Delayed Diagnosis, Female, Humans, Male, Middle Aged, Spain, Autoantibodies immunology, Lung Diseases, Interstitial diagnosis, Lung Diseases, Interstitial immunology, Lung Diseases, Interstitial metabolism, RNA Polymerase III immunology, Scleroderma, Systemic diagnosis, Scleroderma, Systemic immunology, Scleroderma, Systemic metabolism
- Abstract
Objectives: To evaluate the clinical features and survival of patients with positive anti-RNA polymerase III (anti-RNAP III) in a Spanish single centre., Methods: We analysed 221 patients with SSc according to LeRoy and Medsger criteria. Twenty-six patients with positivity for anti-RNAP III antibodies were compared with 195 negative patients. Epidemiological, clinical, immunological features and survival were analysed., Results: In patients with anti-RNAP III positivity diffuse cutaneous SSc (dcSSc) subset was the most prevalent (20, 76.9% vs. 35, 17.9%, p < 0.001), with shorter diagnosis delay (4.11 ± 7.34 years vs. 6.77 ± 9.22 years, p = 0.005). Patients with anti-RNAP III antibodies had higher frequency of arterial hypertension (13, 50% vs. 55, 28.2%, p = 0.024), scleroderma renal crisis (SRC) (3, 11.5% vs. 3, 1.5%, p = 0.023), arthritis (9, 34.6% vs. 35, 17.9%, p = 0.046), tendon friction rubs (4, 15.4% vs. 1, 0.5%, p = 0.001) and contractures (5, 19.2% vs. 10, 5.1%, p = 0.02). There were no differences found in the presence of cancer or in global survival. In the multivariate survival analysis, severe interstitial lung disease (ILD) (HR: 8.61, 95%CI 3.40 - 21.81), pulmonary arterial hypertension (PAH) (HR: 4.05, 95%CI 1.42 - 11.61) and SRC (HR: 17.27, 95%CI 3.36 - 88.97) were the only factors associated with poor prognosis., Conclusions: In this cohort anti-RNAP III antibodies are related with dcSSc subset, shorter diagnostic delay and higher prevalence of musculoskeletal involvement, arterial hypertension and SRC. ILD, PAH and SRC were independent prognostic factors.
- Published
- 2019
29. Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry.
- Author
-
Marí-Alfonso B, Simeón-Aznar CP, Guillén-Del Castillo A, Rubio-Rivas M, Trapiella-Martínez L, Todolí-Parra JA, Rodríguez Carballeira M, Marín-Ballvé A, Iniesta-Arandia N, Colunga-Argüelles D, Castillo-Palma MJ, Sáez-Comet L, Egurbide-Arberas MV, Ortego-Centeno N, Freire M, Vargas Hitos JA, Chamorro AJ, Madroñero-Vuelta AB, Perales-Fraile I, Pla-Salas X, Fernández-De-La-Puebla RA, Fonollosa-Pla V, and Tolosa-Vilella C
- Subjects
- Adult, Aged, Cholangitis mortality, Female, Hepatitis, Autoimmune mortality, Humans, Male, Middle Aged, Prognosis, Registries, Scleroderma, Systemic mortality, Sjogren's Syndrome complications, Sjogren's Syndrome mortality, Spain, Survival Rate, Cholangitis etiology, Hepatitis, Autoimmune etiology, Scleroderma, Systemic complications
- Abstract
Objective: To assess the prevalence and causes of hepatobiliary involvement (HBI) in systemic sclerosis (SSc), to investigate the clinical characteristics and prognosis of SSc patients with HBI (SSc-HBI) and without HBI (SSc-non-HBI), and to compare both groups according to the cutaneous SSc subsets., Methods: In all, 1572 SSc patients were collected in the RESCLE registry up to January 2015, and all hepatobiliary disturbances were recorded. We investigated the HBI-related characteristics and survival from the entire SSc cohort and according to the following cutaneous subsets: diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc), and SSc sine scleroderma (ssSSc)., Results: Out of 1572, 118 (7.5%) patients had HBI. Primary biliary cholangitis (PBC) was largely the main cause (n = 67, 4.3%), followed by autoimmune hepatitis (n = 19, 1.2%), and anti-mitochondrial negative PBC (n = 6, 0.4%). Other causes of HBI were as follows: secondary liver diseases (n = 11, 0.7%), SSc-related HBI (n = 7, 0.4%), nodular regenerative hyperplasia (n = 3, 0.2%), liver cirrhosis (n = 3, 0.2%), and HBI of unknown origin (n = 2, 0.1%). In multivariate analysis, HBI was independently associated to lesser risk of dcSSc (5.1% vs. 24.4%), and higher frequency of calcinosis (26% vs. 18%), left ventricular diastolic dysfunction (46% vs. 27%), sicca syndrome (51% vs. 29%), and anti-centromere antibodies (ACA, 73% vs. 44%). According to the cutaneous subsets, HBI was associated (1) in lcSSc, to longer time from SSc onset to diagnosis (10.8 ± 12.5 vs. 7.2 ± 9.3 years), sicca syndrome (54% vs. 33%), and ACA (80% vs. 56%); (2) in ssSSc, to sicca syndrome (44% vs. 19%), and (3) in dcSSc, no associations were found. HBI was the cause of death in 2.3% patients but the cumulative survival according to the presence or absence of HBI showed no differences., Conclusions: HBI prevalence in SSc is 7.5% and dcSSc is the least involved subset. PBC is the main cause of HBI. Patients with SSc-HBI exhibited specific clinical and immunologic profile. Survival is similar for SSc patients with HBI., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
30. Parathyroid crisis: Hypercalcemia as a medical emergency.
- Author
-
Medina Ortega L, Feijoo Massó C, and Tolosa Vilella C
- Subjects
- Emergencies, Humans, Hyperparathyroidism, Primary complications, Male, Middle Aged, Hypercalcemia etiology, Hyperparathyroidism, Primary diagnosis
- Published
- 2018
- Full Text
- View/download PDF
31. Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review.
- Author
-
Freire M, Rivera A, Sopeña B, Tolosa Vilella C, Guillén-Del Castillo A, Colunga Argüelles D, Callejas Rubio JL, Rubio Rivas M, Trapiella Martínez L, Todolí Parra JA, Rodríguez Carballeira M, Iniesta Arandia N, García Hernández FJ, Egurbide Arberas MV, Sáez Comet L, Vargas Hitos JA, Ríos Blanco JJ, Marín Ballvé A, Pla Salas X, Madroñero Vuelta AB, Ruiz Muñoz M, Fonollosa Pla V, and Simeón Aznar CP
- Subjects
- Cause of Death, Cohort Studies, Female, Humans, Male, Prognosis, Prospective Studies, Scleroderma, Systemic complications, Scleroderma, Systemic epidemiology, Sex Characteristics, Scleroderma, Systemic mortality
- Abstract
Objectives: The low overall prevalence of systemic sclerosis (SSc) and the low proportion of male patients have resulted in a scarcity of studies assessing sex differences in Ssc patients, and contradictory results have often been show among those studies that have been performed., Methods: A prospective study was conducted with the Spanish RESCLE register to analyse the influence of gender on survival of SSc patients., Results: In total, 1506 SSc patients (1341 women, 165 men) were recruited from 21 centres. Older age at onset (OR 1.02), shorter time from onset to diagnosis (OR 0.96), smoking (OR 2.57), interstitial lung disease (ILD) (OR 1.58), less predisposition to sicca syndrome and to antinuclear antibody positivity (OR 0.29 and 0.43, respectively), and higher compliance with the ACR 1980 criteria (OR 1.79) were independently associated with the male sex. During follow-up, 30.4% of men versus 14.6% of women died (p<0.001). Survival at 10 years from the onset of symptoms was 75.3% for men and 92.9% for women (p<0.001), and the difference remained after selecting only SSc-related deaths (85.6% vs. 96.1%, p<0.001). The mortality predictive factors were diffuse SSc (OR 2.26), ILD (OR 1.82), digital ulcers (OR 1.38), tendon friction rubs (OR 1.74), male sex (OR 1.53), increased age at onset (OR 1.13) and isolated PH (considering only deaths from diagnosis), both in the overall (OR 3.63) and female cohorts (OR 3.97). The same risk factors were observed in the male cohort, except for isolated PH and ILD., Conclusions: The present study confirms the existence of epidemiological, clinical, laboratory and prognostic gender differences in systemic sclerosis patients.
- Published
- 2017
32. Infliximab for life-threatening pulmonary artery aneurysms in Behçet's disease. A case report.
- Author
-
Tolosa-Vilella C, Capela CA, Monteagudo-Jiménez M, and Marí-Alfonso B
- Subjects
- Adult, Aneurysm diagnostic imaging, Aneurysm etiology, Behcet Syndrome complications, Female, Humans, Infliximab, Pulmonary Artery diagnostic imaging, Tomography, X-Ray Computed, Aneurysm drug therapy, Anti-Inflammatory Agents therapeutic use, Antibodies, Monoclonal therapeutic use, Behcet Syndrome drug therapy, Severity of Illness Index
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.